论文部分内容阅读
对未经其他治疗的手术摘除的胶质瘤标本，采用免疫组化和原位标记方法研究了胶质瘤及其瘤旁组织中细胞增殖以及凋亡的状况。结果表明，增殖细胞核抗原在世界卫生组织（ＷＨＯ）制定的不同级别的胶质瘤中其阳性率具有显著性差异（Ｐ＝ ０．０００５），而在胶质瘤与其瘤旁组织之间则无显著性差异。恶性程度不同的胶质瘤中细胞发生凋亡的比率具有显著性的差异（Ｐ＝ ０．０１７０），而在胶质瘤与其瘤旁组织间无显著性差异。增殖细胞核抗原是划分胶质瘤恶性程度的一个较好的指标，与Ｗ ＨＯ 胶质瘤恶性程度分级具有较好的相关性（ｒ＝ ０．４０８９）。Ｗ ＨＯ Ⅱ级星形胶质瘤细胞凋亡明显增多，可能是保留了恶性程度较高的胶质瘤细胞而清除了恶性程度相对较低的胶质瘤细胞，从而可能促进了胶质瘤的恶性进展。胶质瘤邻近的瘤旁组织可能已具有了胶质瘤的某些特性，胶质瘤呈浸润性生长可能与此有密切的关系。
For glioma specimens removed by other treatments, immunohistochemistry and in situ labeling methods were used to investigate cell proliferation and apoptosis in gliomas and adjacent tissues. The results showed that the positive rate of proliferating cell nuclear antigen in different grades of gliomas developed by the World Health Organization (WHO) was significantly different (P = 0.0005), but not between gliomas and their adjacent tissues. Significant difference. The rate of apoptosis in gliomas with different degrees of malignancy was significantly different (P = 0.0170), but there was no significant difference between gliomas and their adjacent tissues. Proliferating cell nuclear antigen is a good index to classify the malignancy degree of glioma, and has a good correlation with the grade of malignant degree of WHO glioma (r= 0.4089). Apoptosis of WHO grade II astrocytoma cells increased significantly. It may be that glioma cells with higher degree of malignancy are retained and glioma cells with relatively low degree of malignancy are eliminated, which may promote gliomas. Malignant progress. Adjacent paraneoplastic tissues of gliomas may already have certain characteristics of gliomas, and infiltrative growth of gliomas may be closely related to this.